Order Center
 
Product Catalog →  Cell Biology →  Cell Signaling and Neuroscience →  Peptides and Proteins →  Peptides →  Neuropeptides →  Tachykinins
 Print Preview

Tachykinins

Ascending pain pathways. IL: intralaminar nucleus of the thalamus, VP: ventroposterior nucleus of the thalamus.



Description
Biochem/physiol Actions
Product #
N-Acetyl-L-tryptophan 3,5-bis(trifluoromethyl)benzyl ester ≥99% (TLC), powder Competitive substance P receptor antagonist. It is approximately 1000-fold more potent at cloned human NK-1 receptors than at cloned human NK-2 and NK-3 receptors; and approximately 200-fold more potent at human NK-1 receptors than at rat NK-1 receptors. The IC50 for the human NK-1 receptor expressed in CHO cells is approximately 2 nM.
A5330
Entero-hylambatin >97% (HPLC), powder H4534
GR 64349 >96% Potent and selective agonist at the NK-2 tachykinin receptor.
G113
GR 73632 >97% Potent and specific agonist at the NK-1 tachykinin receptor.
G114
GR 82334 >97% Potent and specific reversible antagonist at the NK-1 tachykinin receptor.
G115
GR 94800 >96%, powder Selective NK-2 tachykinin receptor antagonist.
G130
Hemokinin 1 human ≥98% (HPLC), solid NK1 tachykinin receptor agonist.
H1664
Hylambatin >96% (HPLC) Tachykinin that increases plasma glucose and plasma insulin.
H0409
L-659,877 >95%, powder Potent and selective NK-2 tachykinin receptor antagonist.
L117
L-703,606 oxalate salt hydrate solid Potent and selective non-peptide NK-1 tachykinin receptor antagonist.
L119
L-733,060 hydrochloride solid, ≥98% (HPLC) Non-peptide NK1 tachykinin receptor antagonist; selective for guinea pig/human versus rat/mouse.
L137
L-733,061 hydrochloride solid Weak NK-1 tachykinin receptor antagonist; less active enantiomer of L-733,060 hydrochloride.
L138
MEN-10,376 ≥95% (HPLC), solid Potent and selective NK-2 tachykinin receptor antagonist.
M157
Neurokinin A ≥97% (HPLC) Endogenous tachykinin agonist with preference for the NK-2 receptor, more potent bronchoconstrictor than Substance P.
N4267
Neurokinin B ≥95% (HPLC) Endogenous tachykinin agonist with preference for the NK-3 receptor. Potent bronchoconstrictor; may have neuromodulatory role in brain.
N4143
[β-Ala8]-Neurokinin A Fragment 4-10 ≥97% (HPLC), powder Potent and selective NK-2 tachykinin receptor agonist.
N147
[Ala5, β-Ala8]-α-Neurokinin Fragment 4-10 ≥97% (HPLC) NK-2 tachykinin receptor agonist.
N6144
SB 218795 >98% (HPLC) Non-peptide NK3 tachykinin receptor antagonist.
S8817
SB 222200 ≥98% (HPLC), solid Non-peptide NK3 tachykinin receptor antagonist.
S5192
Substance P acetate salt hydrate ≥95% (HPLC), powder NK-1 agonist; potent vasodilator and hypotensive agent; induces salivation; increases capillary permeability; induces mast cell degranulation; putative neurotransmitter in sensory (pain) afferents.
S6883
Substance P acetate salt hydrate BioChemika, PeptiSelect, ≥98.0% (HPCE) NK-1 agonist; potent vasodilator and hypotensive agent; induces salivation; increases capillary permeability; induces mast cell degranulation; putative neurotransmitter in sensory (pain) afferents.
85965
[D-Arg1, D-Phe5, D-Trp7,9, Leu11]-Substance P ≥97% (HPLC) NK-1 tachykinin receptor antagonist
S3144
[D-Arg1, D-Trp7,9, Leu11]-Substance P acetate salt ≥97% (HPLC) Potent NK-1 tachykinin receptor antagonist.
S0274
[Sar9]-Substance P ≥97% (HPLC) NK-1 receptor agonist.
S6636
[Sar9, Met(O2)11]-Substance P ≥97% (HPLC) Highly selective NK-1 receptor agonist.
S3672
Acetyl-[Arg6, Sar9, Met(O2)11]-Substance P Fragment 6-11 ≥95% Selective NK-1 receptor agonist.
S2275
Succinyl-[Asp6, N-Me-Phe8]-Substance P Fragment 6-11 ≥97% (HPLC) Selective NK-3 tachykinin receptor agonist.
S6772
WIN 51708 hydrate solid WIN 51708 hydrate is a non-peptide NK1 tachykinin receptor antagonist.
W103
WIN 62,577 solid Non-peptide NK1 tachykinin receptor antagonist.
W104

 Site Use Terms Terms and Conditions of Sale Privacy
Copyrights © 2008 Sigma-Aldrich Co. All Rights Reserved. Reproduction of any materials from the site is strictly forbidden without permission. Sigma-Aldrich brand products are sold exclusively through Sigma-Aldrich, Inc.